No psychedelic ETF/large-cap re-rating event occurs in the next 30 days.

The main stock fund tracking psychedelic companies (called PSIL) is expected to stay relatively flat — not jumping or crashing more than 25% — over the next 30 days. Big price swings in this sector usually need a major trigger, like a drug getting approved or a big clinical trial result, and none of those are expected right now.

Sector drifts absent binary catalysts. Near-term, no scheduled FDA action or Phase 3 topline is imminent for the leading psychedelic names, so no sharp re-rate is expected.